Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eddingpharm Acquires China Rights to Insomnia Drug from Australia's Suda

publication date: Nov 9, 2016
Shanghai's Eddingpharm in-licensed China rights to ZolpiMist® from Suda, an Australian drugmaker specializing in oro-mucosal delivery of drugs. ZolpiMist is a reformulation of zolpidem tartrate (Ambien), a short-term treatment for insomnia, delivered via Suda's OroMist® drug delivery platform. Eddingpharm will pay $300,000 upfront and another $200,000 once the product passes CFDA registration testing. Eddingpharm estimates the deal will generate $26 million of revenues for Suda over 15 years. More details....

Stock Symbol: (ASX: SUD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital